Swiss National Bank
CRNX

Swiss National Bank’s Crinetics Pharmaceuticals CRNX Stock Holding History

Swiss National Bank’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.88M Buy
183,800
+7,300
+4% +$271K ﹤0.01% 1260
2026
Q1 		$6.41M Hold
176,500
– – ﹤0.01% 1205
2025
Q4 		$8.22M Buy
176,500
+4,000
+2% +$178K ﹤0.01% 1081
2025
Q3 		$7.18M Buy
172,500
+3,700
+2% +$118K ﹤0.01% 1131
2025
Q2 		$4.85M Buy
168,800
+7,000
+4% +$216K ﹤0.01% 1317
2025
Q1 		$5.43M Buy
161,800
+2,400
+2% +$89.6K ﹤0.01% 1213
2024
Q4 		$8.15M Buy
159,400
+28,500
+22% +$1.59M 0.01% 1044
2024
Q3 		$6.69M Buy
130,900
+600
+0.5% +$30.9K ﹤0.01% 1148
2024
Q2 		$5.84M Buy
130,300
+3,800
+3% +$175K ﹤0.01% 1178
2024
Q1 		$5.92M Buy
126,500
+22,300
+21% +$873K ﹤0.01% 1186
2023
Q4 		$3.71M Sell
104,200
-12,200
-10% -$374K ﹤0.01% 1470
2023
Q3 		$3.46M Buy
116,400
+34,200
+42% +$705K ﹤0.01% 1506
2023
Q2 		$1.48M Buy
82,200
+900
+1% +$17.9K ﹤0.01% 2081
2023
Q1 		$1.31M Sell
81,300
-9,500
-10% -$176K ﹤0.01% 2088
2022
Q4 		$1.66M Buy
90,800
+2,800
+3% +$49.3K ﹤0.01% 2016
2022
Q3 		$1.73M Hold
88,000
– – ﹤0.01% 1971
2022
Q2 		$1.64M Buy
88,000
+9,300
+12% +$186K ﹤0.01% 2056
2022
Q1 		$1.73M Buy
78,700
+7,700
+11% +$156K ﹤0.01% 2120
2021
Q4 		$2.02M Buy
71,000
+21,400
+43% +$528K ﹤0.01% 2055
2021
Q3 		$1.04M Hold
49,600
– – ﹤0.01% 2420
2021
Q2 		$935K Buy
49,600
+12,000
+32% +$211K ﹤0.01% 2505
2021
Q1 		$575K Buy
37,600
+1,400
+4% +$21.7K ﹤0.01% 2446
2020
Q4 		$511K Hold
36,200
– – ﹤0.01% 2458
2020
Q3 		$567K Hold
36,200
– – ﹤0.01% 2334
2020
Q2 		$634K Buy
36,200
+17,400
+93% +$297K ﹤0.01% 2316
2020
Q1 		$276K Buy
18,800
+900
+5% +$18.4K ﹤0.01% 2360
2019
Q4 		$449K Hold
17,900
– – ﹤0.01% 2443
2019
Q3 		$269K Hold
17,900
– – ﹤0.01% 2469
2019
Q2 		$448K Buy
+17,900
New +$443K ﹤0.01% 2446

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss National Bank's CRNX Position: Q2 2026 in Review

Swiss National Bank increased its Crinetics Pharmaceuticals (CRNX) stake by 4.1% in Q2 2026, buying an estimated $271K and bringing the position to 183,800 shares worth $6.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Swiss National Bank first reported a position in CRNX in Q2 2019 and has held it in 29 quarters since. The position peaked at $8.22M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Swiss National Bank held 183,800 shares of Crinetics Pharmaceuticals worth $6.88M as of Q2 2026.
  • Swiss National Bank bought 7,300 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $271K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1260 holding.
  • Swiss National Bank first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Swiss National Bank's Crinetics Pharmaceuticals position peaked at $8.22M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.